Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8349922 | 0.90 | HTR7 (0.50) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL738090 | 0.84 | HTR7 (0.50) | KCNH2HTR7KDM4EDAOHSD17B10 | |
| SCHEMBL8350272 | 0.84 | KDM4E (0.52) | CHRM2CHRM1CHRM3KCNH2HTR7 | |
| Hydrochloric Acid SCHEMBL9725415 | 0.83 | HTR7 (0.49) | KCNH2HTR7KDM4EDAOHSD17B10 | |
| SCHEMBL8885250 | 0.82 | KDM4E (0.53) | CHRM2CHRM1KCNH2HTR7KDM4E | |
| SCHEMBL739228 | 0.81 | HTR7 (0.73) | CHRM2CHRM1CHRM3KCNH2HTR7 | |
| Hydrochloric Acid SCHEMBL9725420 | 0.80 | HTR7 (0.71) | CHRM2CHRM1CHRM3KCNH2HTR7 | |
| SCHEMBL8352432 | 0.78 | LMNA (0.53) | HTR7DAOHSD17B10LMNATSHR | |
| SCHEMBL8350269 | 0.77 | LMNA (0.55) | HTR7DAOHSD17B10LMNATSHR | |
| SCHEMBL737783 | 0.76 | CTDSP1 (0.53) | KDM4EALDH1A1HSD17B10LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138177-B2 | Benzimidazolone derivatives as CB2 receptor ligands | PFIZER INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-1861377-B1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | PFIZER (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | PFIZER INC | 2009-12-03 | — | — | US | disclosed |
| US-20090181957-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | ANDO KAZUO | 2009-07-16 | — | — | US | disclosed |
| EP-1861377-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | Pfizer, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097808-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | PFIZER JAPAN INC. (JP) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | TRPV1, CNR1, CNR2 | CHRM2 135/4885CHRM4 457/4885CHRM5 291/4885 |
| US-20090181957-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | TRPV1, CNR1, CNR2 | CHRM2 81/4885CHRM4 301/4885CHRM5 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.